Gentech, Inc. has designed a Medicare “Market-based Pricing Model” that replaces the average sales price (ASP) method currently used with a new approach, while retaining the current buy-and-bill system. Learn more about this proposed model, which also provides a means for CMS to pass savings on to patients at the point of sale. Find out why Genentech believes the model would accelerate spur private-market negotiations and how it may affect overall ASP and Medicare reimbursement.
CMS Actively Looking For New Reimbursement Pathway For Innovative Devices
- Newsletter
- 3 Pages
- Global
